11Nov 2022
The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48‐week randomized phase 4 study: STAR study

The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48‐week randomized phase 4 study: STAR study

To compare a treat‐and‐extend (TAE) strategy with a fixed dosing regimen of intravitreal conbercept (IVC) for the management of treatment‐naïve polypoidal choroidal vasculopathy (PCV) patients. At 48 weeks, there was no significant difference between the 3 + Q12W group and 3 + TAE group in mean BCVA improvement, mean changes in central retinal thickness (CRT), maximum retinal thickness (MRT), pigment epithelial detachment (PED) height, PED volume, branching vascular network (BVN) area, polypoidal lesion number, polypoidal lesion area, rates of patients who avoided vision loss of ≥15 ETDRS letters or complete polypoidal lesion regression rate. Both 3 + Q12W and 3 + TAE IVC regimens could improve visual and anatomical outcomes in PCV patients.

  • #ophthalmology

Like

Save

Share